GE HealthCare to Acquire SOFIE Biosciences for U.S. PET Radiopharmaceuticals
GE HealthCare announced it will acquire SOFIE Biosciences to expand its presence in the U.S. radiopharmaceutical market. This acquisition aims to improve patient access to F18 labeled Positron Emission Tomography (PET) radiopharmaceuticals and strengthen GE's position in the growing Pharmaceutical Diagnostics (PDx) sector by establishing a 'final mile' supply footprint.
GE HealthCare·


